866 Malcolm Road, Suite 100
8 articles with ALX Oncology
ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
New Clinical Data Presented at the 2019 American Society of Clinical Oncology in Chicago, IL
ALX Oncology announced that Jaume Pons, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 4:00 p.m. ET at the Grand Hyatt in New York, NY.
ALX Oncology to Present ALX148 Clinical Data at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
ALX Oncology announced that ALX148 clinical results have been selected for presentation in the Poster Discussion Session at the 2019 ASCO Annual Meeting, May 31 – June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.
ALX Oncology announced that preclinical data for its SIRPα antibody research program will be presented at the 2019 Keystone Symposia Conference, Cancer Immunotherapy in Whistler, British Columbia and the American Association for Cancer Research Annual Meeting 2019 in Atlanta, Georgia.
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
Updated Clinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting in Washington, D.C.
The new name and logo will differentiate ALX Oncology (ALX) from other companies in the field as the Company advances its clinical programs.
Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma
Alexo Therapeutics presented data from the first-in-human Phase 1 study of its lead candidate, ALX148, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Alexo Therapeutics Initiates ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors and Lymphoma
Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.